Rui Avelar
Chief Tech/Sci/R&D Officer at EVOLUS, INC.
Net worth: 4 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Moatazedi | M | 46 | 6 years | |
| Robert Hayman | M | 65 |
AEON Biopharma Sub, Inc.
 AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | 10 years |
| Karah Parschauer | F | 46 | 5 years | |
| Brady Stewart | M | 48 | 2 years | |
| Kurt Knab | M | - | 6 years | |
| David Gill | M | 69 | 6 years | |
| Vikram Malik | M | 61 |
AEON Biopharma Sub, Inc.
AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | 10 years |
| Simone Blank | F | 61 | 6 years | |
| Nareg Sagherian | M | - | - | |
| Christopher Paige | M | 71 |
University of Toronto
| 37 years |
| Jeffrey J. Plumer | M | - | 10 years | |
| Jost Fischer | M | 69 |
AEON Biopharma Sub, Inc.
AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | 7 years |
| Harry Ruda | M | 65 |
University of Toronto
| 35 years |
| Dan Stewart | M | - | 3 years | |
| Jessica Novak | F | - | 3 years | |
| Christos Monovoukas | M | - | 2 years | |
| Sandra Beaver | F | 46 | 2 years | |
| Tomoko Yamagishi-Dressler | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Murthy Simhambhatla | M | 58 |
AEON Biopharma Sub, Inc.
AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | 3 years |
| J. Marmo | M | 55 | - | |
| Stuart R. Nayman | M | - |
University of Toronto
| 7 years |
| Ashwin K. Agarwal | M | - | 3 years | |
| Kristine Romine | M | 59 |
AEON Biopharma Sub, Inc.
AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | 3 years |
| Valdis Martinsons | M | - |
University of Toronto
| 7 years |
| Bosun Hau | M | 45 |
AEON Biopharma Sub, Inc.
AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | 2 years |
| Joseph Cargnelli | M | 54 |
University of Toronto
| 6 years |
| John Docherty | M | 53 |
University of Toronto
| 6 years |
| Chris Ouslis | M | - |
University of Toronto
| 6 years |
| Davin Andrew Gibbins | M | - |
University of Toronto
| 5 years |
| Andrew Pyle | M | - |
University of Toronto
| 5 years |
| Brian Miron | M | - |
University of Toronto
| 5 years |
| Andrew Woo | M | - |
University of Toronto
| 6 years |
| Crystal Muilenburg | F | 45 | 4 years | |
| Wai Cheong Ng | M | 55 |
University of Toronto
| 7 years |
| Fiona J. Kelly | F | - |
University of Toronto
| 3 years |
| Ira Kagan | M | 61 |
University of Toronto
| 7 years |
| Hamid Mumin | M | - |
University of Toronto
| 4 years |
| Bob Rhatigan | M | - |
AEON Biopharma Sub, Inc.
AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | - |
| Jonathan Anschell | M | 56 |
University of Toronto
| 6 years |
| Cheong Szeto | M | 54 |
University of Toronto
| 6 years |
| Kris Garcia | M | - | - | |
| Michael Mazen Jafar | M | 42 | 3 years | |
| Anna Marie Tham | F | 60 |
University of Toronto
| 6 years |
| Flora Wood | F | - |
University of Toronto
| 5 years |
| Mazen Hassounah | M | - |
University of Toronto
| 5 years |
| Richard Romano | M | - |
University of Toronto
| 6 years |
| Bill Maslechko | M | 63 |
University of Toronto
| 4 years |
| Lauren Silvernail | F | 65 | 4 years | |
| Gerald D. Mintz | M | 71 |
University of Toronto
| 3 years |
| Peter Farrell | M | 81 | - | |
| Alicia Damley | F | - |
University of Toronto
| 7 years |
| Kwok Cheung Chan | M | 62 |
University of Toronto
| 6 years |
| Jon A. Douglas | M | 61 |
University of Toronto
| 4 years |
| Anna Marks | F | - |
University of Toronto
| 4 years |
| Suneet Singh Tuli | M | 54 |
University of Toronto
| 4 years |
| Colin White | M | - |
University of Toronto
| 4 years |
| Chi Yu Yu | M | 63 |
University of Toronto
| 4 years |
| Hugues Simard | M | 56 |
University of Toronto
| 4 years |
| Warren John Stoddart | M | - |
University of Toronto
| 4 years |
| Jim Athanasopoulos | M | 54 |
University of Toronto
| 4 years |
| David William Briggs | M | - |
University of Toronto
| 4 years |
| C. Barry McLean | M | - |
University of Toronto
| 2 years |
| Jill A. MacRae | F | - |
University of Toronto
| 4 years |
| Monique Rabideau | F | - |
University of Toronto
| 3 years |
| Tom Meyer | M | 56 |
University of Toronto
| 4 years |
| Ene Liis Palmer | F | - |
University of Toronto
| 3 years |
| Dennis Wolf | M | 71 |
AEON Biopharma Sub, Inc.
AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | 1 years |
| Lucy Chow | F | - |
University of Toronto
| 2 years |
| Elmer Kim | M | - |
University of Toronto
| 4 years |
| Domenic A. Rinaldi | M | - |
University of Toronto
| 4 years |
| Colin Foster | M | 61 |
University of Toronto
| 4 years |
| Alison Wright | F | - |
University of Toronto
| 4 years |
| Caroline Gillespie | F | - |
University of Toronto
| 5 years |
| Shuk Kwan Lui | F | 58 |
University of Toronto
| 4 years |
| Brian Ostroff | M | - |
University of Toronto
| 4 years |
| Gregory P. Downey | M | - |
University of Toronto
| 4 years |
| Michael Vinke | M | - |
University of Toronto
| 3 years |
| Paul Mancuso | M | 59 |
University of Toronto
| 4 years |
| Howard Verrico | M | - |
University of Toronto
| 3 years |
| Jason Lester | M | 62 |
University of Toronto
| 4 years |
| Victor Alksnis | M | - |
University of Toronto
| 4 years |
| Rudy Gobin | M | 62 |
University of Toronto
| 4 years |
| Brian T. McGee | M | 63 |
University of Toronto
| 4 years |
| Philip Evershed | M | 63 |
University of Toronto
| 1 years |
| Kresimir Begic | M | - |
University of Toronto
| 4 years |
| Wendy Ford | F | - |
University of Toronto
| 4 years |
| MacMurray D. Whale | M | - |
University of Toronto
| 4 years |
| Jim McGovern | M | 61 |
University of Toronto
| 4 years |
| Mark Kociancic | M | 54 |
University of Toronto
| 4 years |
| Christopher Wei | M | 55 |
University of Toronto
| 4 years |
| Ara P. Arzumanian | M | 55 |
University of Toronto
| 4 years |
| Clifford Hale-Sanders | M | - |
University of Toronto
| 4 years |
| Wai Yee Yiu | F | 56 |
University of Toronto
| 4 years |
| James Ngai | M | 61 |
University of Toronto
| 4 years |
| Catherine Elizabeth Payne | F | - |
University of Toronto
| 4 years |
| Kelly Battle | F | - |
University of Toronto
| 4 years |
| Trevor Haynes | M | 57 |
University of Toronto
| 4 years |
| Raja Arian Abbasi | M | 58 |
University of Toronto
| 4 years |
| Heather Takahashi | F | - |
University of Toronto
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 71 | 71.72% |
| United States | 28 | 28.28% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Rui Avelar
- Personal Network